COMMUNIQUÉS West-GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units (“RSUs”) to two newly-hired non-executive [...]
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
02/03/2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a [...]
Myriad Commercially Launches Precise MRD with Select Community Oncologists
02/03/2026
Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, [...]
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
02/03/2026
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2025 Results; Sets 2026 Guidance; Announces Share Repurchase Program
02/03/2026
BRENTWOOD, Tenn., March 02, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the [...]
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
02/03/2026
Fourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 million, a 36% increase [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/03/2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
02/03/2026
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
02/03/2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
02/03/2026
Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Immuneering to Present at the Leerink Global Healthcare Conference
02/03/2026
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that [...]
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/03/2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192, [...]
EssilorLuxottica: Disclosure of transactions in own shares
02/03/2026
Disclosure of transactions in own shares Paris, France (March 2, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that on [...]
IBA – ACQUISITION D’ACTIONS PROPRES
02/03/2026
Louvain-la-Neuve, Belgique, 2 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique [...]
IBA – ACQUISITION OF OWN SHARES
02/03/2026
IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 2 nd , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion [...]
RadNet, Inc. to Present at the Raymond James 47th Annual Institutional Investors Conference on Tuesday, March 3rd, 2026
02/03/2026
LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]

Pages